DK3853220T3 - Quinazolinderivater som antitumormidler - Google Patents
Quinazolinderivater som antitumormidler Download PDFInfo
- Publication number
- DK3853220T3 DK3853220T3 DK19862146.8T DK19862146T DK3853220T3 DK 3853220 T3 DK3853220 T3 DK 3853220T3 DK 19862146 T DK19862146 T DK 19862146T DK 3853220 T3 DK3853220 T3 DK 3853220T3
- Authority
- DK
- Denmark
- Prior art keywords
- antitumor agents
- quinazoline derivatives
- quinazoline
- derivatives
- antitumor
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018106098 | 2018-09-18 | ||
| CN2019091078 | 2019-06-13 | ||
| PCT/CN2019/106233 WO2020057511A1 (en) | 2018-09-18 | 2019-09-17 | Quinazoline derivatives as antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3853220T3 true DK3853220T3 (da) | 2024-03-04 |
Family
ID=69888359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19862146.8T DK3853220T3 (da) | 2018-09-18 | 2019-09-17 | Quinazolinderivater som antitumormidler |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11723908B2 (da) |
| EP (2) | EP3853220B1 (da) |
| JP (1) | JP2022501338A (da) |
| KR (1) | KR20210061329A (da) |
| CN (1) | CN112654612A (da) |
| AU (1) | AU2019341273A1 (da) |
| CA (1) | CA3099776A1 (da) |
| DK (1) | DK3853220T3 (da) |
| FI (1) | FI3853220T3 (da) |
| LT (1) | LT3853220T (da) |
| PT (1) | PT3853220T (da) |
| SI (1) | SI3853220T1 (da) |
| WO (1) | WO2020057511A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778589B1 (en) * | 2018-04-09 | 2022-05-11 | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN111377850B (zh) * | 2018-12-31 | 2022-10-18 | 艾琪康医药科技（上海）有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| TWI820414B (zh) * | 2020-04-17 | 2023-11-01 | 大陸商北京賽特明強醫藥科技有限公司 | 喹唑啉類化合物、製備方法及其應用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| JP2024510312A (ja) * | 2021-03-19 | 2024-03-06 | 北京賽特明強医薬科技有限公司 | キナゾリン系化合物、キナゾリン系化合物の組成物及び応用 |
| WO2022271630A1 (en) * | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Egfr inhibitors |
| CN117858872A (zh) * | 2021-06-22 | 2024-04-09 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| WO2022271749A1 (en) * | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| CN117836286A (zh) * | 2021-06-22 | 2024-04-05 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| WO2023066296A1 (en) * | 2021-10-20 | 2023-04-27 | Suzhou Zanrong Pharma Limited | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof |
| WO2023177592A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3934085A (en) | 1984-01-30 | 1985-08-09 | Icrf Patents Ltd. | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| DZ3407A1 (da) | 2000-06-22 | 2001-12-27 | Pfizer Prod Inc | |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| US20050043336A1 (en) * | 2001-11-03 | 2005-02-24 | Hennequin Laurent Francois Andre | Quinazoline derivatives as antitumor agents |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1660090B1 (en) | 2003-08-14 | 2012-11-21 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| DE602006021645D1 (de) * | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| CN101611041A (zh) * | 2006-12-12 | 2009-12-23 | 武田药品工业株式会社 | 稠合杂环化合物 |
| WO2017148391A1 (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| US11525008B2 (en) * | 2016-09-22 | 2022-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| WO2019042409A1 (zh) * | 2017-09-01 | 2019-03-07 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| JP7296641B2 (ja) * | 2017-12-19 | 2023-06-23 | チェンドゥ・ジンルイ・ファウンデーション・バイオテック・カンパニー・リミテッド | キナゾリン誘導体およびその使用 |
| WO2019214651A1 (zh) * | 2018-05-08 | 2019-11-14 | 南京明德新药研发有限公司 | 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
| AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
-
2019
- 2019-09-17 DK DK19862146.8T patent/DK3853220T3/da active
- 2019-09-17 PT PT198621468T patent/PT3853220T/pt unknown
- 2019-09-17 KR KR1020217003251A patent/KR20210061329A/ko unknown
- 2019-09-17 EP EP19862146.8A patent/EP3853220B1/en active Active
- 2019-09-17 US US17/051,176 patent/US11723908B2/en active Active
- 2019-09-17 LT LTEPPCT/CN2019/106233T patent/LT3853220T/lt unknown
- 2019-09-17 CA CA3099776A patent/CA3099776A1/en active Pending
- 2019-09-17 EP EP23219357.3A patent/EP4360713A2/en active Pending
- 2019-09-17 CN CN201980044137.8A patent/CN112654612A/zh active Pending
- 2019-09-17 SI SI201930718T patent/SI3853220T1/sl unknown
- 2019-09-17 JP JP2021514381A patent/JP2022501338A/ja active Pending
- 2019-09-17 FI FIEP19862146.8T patent/FI3853220T3/fi active
- 2019-09-17 AU AU2019341273A patent/AU2019341273A1/en active Pending
- 2019-09-17 WO PCT/CN2019/106233 patent/WO2020057511A1/en active Application Filing
-
2023
- 2023-05-18 US US18/319,509 patent/US20230293533A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI3853220T3 (fi) | 2024-02-22 |
| EP3853220A4 (en) | 2022-06-22 |
| CN112654612A (zh) | 2021-04-13 |
| EP3853220B1 (en) | 2024-01-03 |
| EP4360713A2 (en) | 2024-05-01 |
| US20230293533A1 (en) | 2023-09-21 |
| JP2022501338A (ja) | 2022-01-06 |
| LT3853220T (lt) | 2024-03-12 |
| US20210386742A1 (en) | 2021-12-16 |
| WO2020057511A1 (en) | 2020-03-26 |
| US11723908B2 (en) | 2023-08-15 |
| CA3099776A1 (en) | 2020-03-26 |
| SI3853220T1 (sl) | 2024-04-30 |
| PT3853220T (pt) | 2024-02-22 |
| AU2019341273A1 (en) | 2020-11-19 |
| EP3853220A1 (en) | 2021-07-28 |
| KR20210061329A (ko) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3853220T3 (da) | Quinazolinderivater som antitumormidler | |
| DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
| DK3510034T3 (da) | Substituerede imidazo-quinoliner som nlrp3-modulatorer | |
| DK3573877T3 (da) | Løbeværk | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| DK3464309T3 (da) | Phosphoramidatnukleosidderivater som anticancermidler | |
| DK3728207T3 (da) | Quinazolinoner som parp14-inhibitorer | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| DK3672951T3 (da) | Quinoxalinderivater som adenosinreceptorantagonister | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK3666787T3 (da) | Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat | |
| ES2968023T3 (es) | Derivados de oxoisoquinolina novedosos | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| DK4056557T3 (da) | Benzazepinderivater nyttige som medikamenter | |
| DK3738452T3 (da) | Fordamper | |
| DK3645539T3 (da) | Pyrido-imidazo-rifamycin-derivater som antibakterielt middel | |
| DK3630729T3 (da) | Pyrimidinforbindelse | |
| DK3484875T3 (da) | Pyrazolylaminobenzimidazolderivater som JAK-hæmmere | |
| MA44018A (fr) | Dérivés de tétrahydroisoquinoline | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| DK3770162T3 (da) | Dihydrochromenderivater | |
| DK3642202T3 (da) | Dihydro-pyrrolo-pyridin-derivater |